Agreement to produce similar biotherapeutic product in Turkey

Generics and biosimilars Initiative

Building trust in cost-effective treatments

Inscribirse
eng / esp

Agreement to produce similar biotherapeutic product in Turkey

INICIO/Noticias Farmacéuticas | Posted 05/11/2021 0 Post your comment

On 22 October 2021, an important agreement was signed between Nobel Pharmaceuticals and the IBG-OzBio partnership for the manufacturing of a similar biotherapeutic product in Turkey. This hopes to be a springboard for further collaborations and medicinal product development in the country.

The similar biotherapeutic product is used to treat a rare disease and has been jointly developed by IBG and OzBio and will now be manufactured by Nobel in Turkey.

The Scientific and Technological Research Council of Turkey (TÜBİTAK) has stepped in to facilitate the production of the similar biotherapeutic product in Turkey. This requires import of the cell clone that produces the similar biotherapeutic product which was developed jointly by Turkey-based IBG and US-based OzBio. Following this, Turkey-based Nobel will lead the development of the similar biotherapeutic product within the country.

This is part of TÜBİTAK’s ‘cooperation before competition’ initiative which, in this case, hopes to bring the four organizations together to successfully develop, trial and launch the similar biotherapeutic product. This is a pivotal point for drug development in Turkey. It hopes to decrease the countries dependency on drug imports and help Turkey become a country that designs, develops and produces medicines and healthcare technology.

Dr Reddy’s and TRPharm collaborate on biosimilars in Turkey

Merck Millipore to collaborate with Turkish firm on biosimilars

LATIN AMERICAN FORUM The new section of the ‘Latin American Forum’ on GaBI has been launched. The objective of this new section is to provide you with all the latest news and updates on developments of generic and biosimilar medicines in Latin America in Spanish. View last week’s headline article: Los datos apoyan la intercambiabilidad de los biosimilares de la UE Browse the news in the Latin American Forum! Register to receive the GaBI Latin American Forum newsletter. Inform colleagues and friends of this new initiative. LATIN AMERICAN FORUM Se ha lanzado la nueva sección del ‘Foro Latinoamericano’ sobre GaBI. El objetivo de esta nueva sección es brindarle las últimas noticias y actualizaciones sobre desarrollos de medicamentos genéricos y biosimilares en América Latina en español. Vea el artículo principal de la semana pasada: Los datos apoyan la intercambiabilidad de los biosimilares de la UE Explore las noticias en el Foro Latinoamericano! Regístrese para recibir el boletín informativo GaBI Foro Latinoamericano. Informe a colegas y amigos sobre esta nueva iniciativa.

Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.